Physician profile
David E Shupe
NPI 1306192372
$2,562.93
in general payments reported to CMS, 2019-2025
18 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $789 · 2021: $115 · 2022: $89.68 · 2023: $189 · 2024: $322 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $540.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $447.69 | 2019-2024 | Farxiga |
| Astellas Pharma US INC | $220.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $218.34 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $196.87 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $145.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.13 | 2019-2023 | Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $110.16 | 2019-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $104.68 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $79.32 | 2019-2024 | Verquvo |
| Amgen INC. | $74.82 | 2019-2020 | |
| Amarin Pharma, INC. | $72.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.79 | 2025 | Xifaxan |
| Abbvie INC. | $62.87 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $34.32 | 2025 | Vowst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $23.59 | 2025 | Kcentra |
| Lexicon Pharmaceuticals, INC. | $21.96 | 2024 | |
| Genentech USA, INC. | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.